TY - JOUR

T1 - БАЛОКСАВИР ПРИ ГРИППЕ У ДЕТЕЙ И ПОДРОСТКОВ: СИСТЕМАТИЧЕСКИЙ ОБЗОР КОНТРОЛИРУЕМЫХ ИССЛЕДОВАНИЙ

AU - ГОРЕЛОВ, А.В.

AU - Лобзин, Юрий Владимирович

AU - Жданов, Константин Валерьевич

AU - Бабаченко, И. В.

AU - РЫЧКОВА, С.В.

AU - Дмитриев, Александр Сергеевич

PY - 2025

Y1 - 2025

N2 - Diseases caused by influenza viruses are a significant public health problem. According to the World Health Organization, there are approximately 1 billion cases of seasonal influenza each year. Approximately 10% of influenza infections occur in children under 10 years of age. Objective. To describe the efficacy of therapy including baloxavir, compared with other antiviral agents and placebo, on the duration of influenza symptoms and viral shedding in influenza in children and adolescents, as measured by clinical trials and real-world clinical practice studies. A systematic review of controlled trials of the efficacy of baloxavir in pediatric influenza compared with other neuraminidase inhibitors and placebo was performed. The review included the results of 11 randomized and non-randomized trials involving 2,262 children and adolescents from 0 to 19 years of age. Ten studies showed a shorter duration of febrile period with baloxavir therapy compared with neuraminidase inhibitors, oseltamivir, laninamivir and placebo combined. Data from four studies confirmed that the use of baloxavir significantly reduced the time to cessation of viral shedding compared with oseltamivir and placebo. The same studies showed a reduction in time to relief of signs and symptoms of influenza with baloxavir therapy compared to placebo. Analysis of safety data showed that the incidence of adverse events with baloxavir was comparable to that with oseltamivir and placebo. Characteristic adverse events during baloxavir administration are gastrointestinal disorders. Conclusion. A systematic review of eleven studies demonstrated a positive effect of baloxavir in influenza in children and adolescents on the duration of febrile period and time to cessation of viral shedding, as well as a favorable safety profile of baloxavir when used in children and adolescents.

AB - Diseases caused by influenza viruses are a significant public health problem. According to the World Health Organization, there are approximately 1 billion cases of seasonal influenza each year. Approximately 10% of influenza infections occur in children under 10 years of age. Objective. To describe the efficacy of therapy including baloxavir, compared with other antiviral agents and placebo, on the duration of influenza symptoms and viral shedding in influenza in children and adolescents, as measured by clinical trials and real-world clinical practice studies. A systematic review of controlled trials of the efficacy of baloxavir in pediatric influenza compared with other neuraminidase inhibitors and placebo was performed. The review included the results of 11 randomized and non-randomized trials involving 2,262 children and adolescents from 0 to 19 years of age. Ten studies showed a shorter duration of febrile period with baloxavir therapy compared with neuraminidase inhibitors, oseltamivir, laninamivir and placebo combined. Data from four studies confirmed that the use of baloxavir significantly reduced the time to cessation of viral shedding compared with oseltamivir and placebo. The same studies showed a reduction in time to relief of signs and symptoms of influenza with baloxavir therapy compared to placebo. Analysis of safety data showed that the incidence of adverse events with baloxavir was comparable to that with oseltamivir and placebo. Characteristic adverse events during baloxavir administration are gastrointestinal disorders. Conclusion. A systematic review of eleven studies demonstrated a positive effect of baloxavir in influenza in children and adolescents on the duration of febrile period and time to cessation of viral shedding, as well as a favorable safety profile of baloxavir when used in children and adolescents.

KW - adolescents

KW - baloxavir

KW - children

KW - influenza

UR - https://www.mendeley.com/catalogue/964b845f-102a-3bb2-b6bc-1f6ef9e1800e/

U2 - 10.20953/1729-9225-2024-3-83-91

DO - 10.20953/1729-9225-2024-3-83-91

M3 - статья

VL - 22

SP - 83

EP - 91

JO - ИНФЕКЦИОННЫЕ БОЛЕЗНИ

JF - ИНФЕКЦИОННЫЕ БОЛЕЗНИ

SN - 1729-9225

IS - 3

ER -